Therapeutic potential of adipose derived stromal cells for major skin inflammatory diseases

Marina Ramírez Galera1, Jesper Svalgaard2, Anders Woetmann1

  • 1The LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Frontiers in Medicine
|March 11, 2024
PubMed

Insights

Adipose-derived mesenchymal stromal cells (AD-MSCs) show promise for treating inflammatory skin diseases like psoriasis and atopic dermatitis. These cells offer immunomodulatory benefits, addressing limitations of current therapies.

Area of Science:

  • Dermatology and Immunology
  • Regenerative Medicine

Background:

  • Psoriasis and atopic dermatitis are chronic inflammatory skin diseases with increasing prevalence.
  • Current treatments have limitations including adverse effects and drug resistance, creating an unmet need for novel therapies.

Purpose of the Study:

  • To review the potential of adipose-derived mesenchymal stromal cells (AD-MSCs) as a new therapeutic option for inflammatory skin conditions.
  • To summarize preclinical and clinical evidence for AD-MSCs in dermatology.
  • To address limitations and clinical questions regarding AD-MSC therapy.

Main Methods:

  • Review of preclinical and clinical studies on adipose-derived mesenchymal stromal cells (AD-MSCs).
  • Analysis of immunomodulatory and anti-inflammatory properties of AD-MSCs.
  • Evaluation of dermatological applications and clinical data.

Main Results:

  • Adipose-derived mesenchymal stromal cells (AD-MSCs) possess significant immunomodulatory and anti-inflammatory properties.
  • Preclinical and clinical studies suggest potential efficacy for AD-MSCs in treating inflammatory skin diseases.
  • Current research highlights AD-MSCs as a promising therapeutic avenue.

Conclusions:

  • Adipose-derived mesenchymal stromal cells (AD-MSCs) represent a promising, cutting-edge treatment for chronic inflammatory skin diseases.
  • Further research is needed to address limitations and unresolved clinical questions for widespread AD-MSC application in dermatology.